Related Experiment Video

Updated: May 22, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma

Ivaylo Gentschev1, Marion Adelfinger, Rafael Josupeit

  • 1Genelux Corporation, San Diego Science Center, San Diego, California, United States of America.

Plos One
|May 23, 2012
PubMed

Insights

Oncolytic vaccinia virus (VACV) therapy shows promise for canine cancer. Two VACV strains effectively targeted canine soft tissue sarcoma cells and inhibited tumor growth in a mouse model, with one strain achieving complete regression and long-term survival.

Area of Science:

  • Veterinary Oncology
  • Virology
  • Immunology

Background:

  • Canine cancer therapy requires novel strategies.
  • Oncolytic vaccinia virus (VACV) strains offer a promising approach.
  • Canine soft tissue sarcoma (CSTS) is a prevalent malignancy.

Purpose of the Study:

  • Establish an in vivo model for CSTS using the STSA-1 cell line.
  • Evaluate the oncolytic and immunological effects of two VACV strains (LIVP1.1.1 and GLV-1h68) against CSTS.
  • Assess the therapeutic potential of VACV virotherapy for canine cancer.

Main Methods:

  • Utilized the STSA-1 cell line for in vitro studies.
  • Developed a canine sarcoma tumor xenograft mouse model for in vivo experiments.
  • Administered LIVP1.1.1 and GLV-1h68 VACV strains systemically.
  • Monitored tumor growth, regression, survival rates, and intratumoral immune cell infiltration.

Main Results:

  • Both VACV strains efficiently infected and destroyed STSA-1 cells in vitro.
  • Systemic VACV administration significantly inhibited tumor growth in the xenograft model.
  • LIVP1.1.1 treatment led to near-complete tumor regression and prolonged survival.
  • VACV replication induced strong oncolysis and significant intratumoral immune cell infiltration, primarily neutrophils.

Conclusions:

  • Oncolytic vaccinia virus (VACV) demonstrates significant potential for treating canine soft tissue sarcoma (CSTS).
  • Direct viral oncolysis and virus-dependent immune cell activation are key anti-tumor mechanisms.
  • The LIVP1.1.1 VACV strain shows particular efficacy, offering a promising therapeutic candidate for CSTS.

More Related Videos

Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.